Abstract: Provided is a pharmaceutical composition for the treatment and prevention of obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, comprising: a therapeutically effective amount of a compound represented by Formula I below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof. wherein R1 through R8 and n are as defined in this disclosure.
Type:
Grant
Filed:
April 25, 2013
Date of Patent:
June 30, 2015
Assignees:
MD BIOALPHA CO., LTD., KT & G CO., LTD.
Inventors:
Sang-Ku Yoo, Myunggyu Park, In Geun Jo, Taehwan Kwak
Abstract: Provided is a method capable of effectively treating various diseases associated with energy excess, such as obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, via elevation of an NAD(P)+/NAD(P)H ratio by increasing an NAD(P)+ concentration in vivo or in vitro through use of NAD(P)H as a substrate or coenzyme by oxidoreductase such as NAD(P)H:quinone oxidoreductase (NQO1), a method of screening a drug for the same and a therapeutic drug.
Type:
Application
Filed:
December 19, 2013
Publication date:
April 17, 2014
Applicant:
MD BIOALPHA CO., LTD.
Inventors:
Myung-Gyu PARK, Sang-Ku YOO, In Geun JO, Taehwan KWAK
Abstract: Provided is a pharmaceutical composition for the treatment and prevention of obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, comprising: a therapeutically effective amount of a compound represented by Formula I below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof. wherein R1 through R8 and n are as defined in this disclosure.
Type:
Application
Filed:
April 25, 2013
Publication date:
September 19, 2013
Applicants:
KT & G CO., LTD., MD BIOALPHA CO., LTD.
Inventors:
Sang-Ku YOO, Myunggyu PARK, In Geun JO, Taehwan KWAK
Abstract: Provided is a pharmaceutical composition for the treatment and prevention of obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, comprising: a therapeutically effective amount of a compound represented by Formula I below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.
Type:
Grant
Filed:
May 22, 2009
Date of Patent:
June 18, 2013
Assignees:
MD Bioalpha Co., Ltd., KT & G Co., Ltd.
Inventors:
Sang-Ku Yoo, Myunggyu Park, In Geun Jo, Taehwan Kwak
Abstract: The present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives as an effective ingredient. More specifically, the present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives that exhibit superior activity in enhancing metabolic activity, as an effective ingredient.
Abstract: Provided is a composition that contains, as an active ingredient, an extract or polysaccharides separated from the leaves and/or stems of plants belonging to Panax genus, for an anticancer drug or its adjuvant, having an effect on the activity of hematopoiesis enhancement, cancer metastasis inhibition, bone marrow defense, etc. . . . , and a process for preparation of the extract from the leaves and/or stems of plants belonging to Panax genus.
Type:
Grant
Filed:
May 28, 2003
Date of Patent:
March 8, 2011
Assignee:
MD Bioalpha Co., Ltd.
Inventors:
Tae Hwan Kwak, Myoung Sook Shin, Ji Yeon Kim, Jong-Kook Park
Abstract: Provided is a composition comprising, as an active ingredient, at least one material selected from the group consisting of uridine and derivatives thereof which promote synthesis of hyaluronic acid in animal and human cell and body, and a pharmaceutical preparation containing the same. The composition and pharmaceutical preparation of the present invention is effective in the treatment and prevention of dry eye syndrome.
Abstract: The present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives as an effective ingredient. More specifically, the present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives that exhibit superior activity in enhancing metabolic activity, as an effective ingredient.
Abstract: Provided is a pharmaceutical composition for the treatment and prevention of obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, comprising: a therapeutically effective amount of a compound represented by Formula I below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.
Type:
Application
Filed:
May 22, 2009
Publication date:
November 26, 2009
Applicants:
MD BIOALPHA CO., LTD., KT & G CO., LTD.,
Inventors:
Sang-Ku Yoo, Myunggyu Park, In Geun Jo, Taehwan Kwak
Abstract: Provided is a method capable of effectively treating various diseases associated with energy excess, such as obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, via elevation of an NAD(P)+/NAD(P)H ratio by increasing an NAD(P)+ concentration in vivo or in vitro through use of NAD(P)H as a substrate or coenzyme by oxidoreductase such as NAD(P)H:quinone oxidoreductase (NQO1), a method of screening a drug for the same and a therapeutic drug.
Type:
Application
Filed:
February 15, 2007
Publication date:
August 27, 2009
Applicant:
MD BIOALPHA CO., LTD.
Inventors:
Myung-Gyu Park, Sang-Ku Yoo, In Geun Jo, Taehwan Kwak
Abstract: Provided is a composition comprising, as an active ingredient, at least one material selected from the group consisting of uridine and derivatives thereof which promote synthesis of hyaluronic acid in animal and human cell and body, and a pharmaceutical preparation containing the same. The composition and pharmaceutical preparation of the present invention is effective in the treatment and prevention of dry eye syndrome.
Abstract: Provided is a pharmaceutical composition for the treatment and prevention of obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, comprising: a therapeutically effective amount of a compound represented by Formula I below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.
Type:
Application
Filed:
February 15, 2006
Publication date:
June 19, 2008
Applicants:
MD BIOALPHA CO., LTD., KT & G CO., LTD.,
Inventors:
Sang-Ku Yoo, Myunggyu Park, In Geun Jo, Taehwan Kwak
Abstract: The present invention provides methods for preparation of metallic amino acid chelates that are electrically neutral and free of interfering ions, by reacting a metal carbonate and an acidic amino acid in an aqueous solution, and the uses of said metallic amino acid chelates. The metallic amino acid chelates can be added to a product such as medical supplies, foods, beverages, cosmetics, feeds, etc., with maintaining the stability of the product at a variety of temperature and pH ranges and also having no effect on the properties of the product, including taste and appearance.
Abstract: The present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives as an effective ingredient. More specifically, the present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives that exhibit superior activity in enhancing metabolic activity, as an effective ingredient.